WUXITECAN-2

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Mar 2026 filing date already counts against anyone who files later.

Record

Serial number

99726259

Mark type

Word mark

Filed

26 Mar 2026

Published for opposition

01 Dec 2026

Attorney of record

Candice Reder

Goods and services

• Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Chemical reagents, other than for medical or veterinary purpose; Biochemical catalysts; Biological preparations for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Heterocyclic compounds; Chemical preparations for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Antibody reagents used for the detection of antigens in cells and tissue, other than for medical or veterinary purposes
• Class 005 — Pharmaceuticals: antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical preparations for inhibiting tumors; antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical products for the prevention and treatment of cancer; Biological preparations for the treatment of cancer; Biological preparations for use in cell cultures for medical purposes; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical purposes; Antibodies for medical purposes; Biologics in the nature of cells for the treatment of cancer
• Class 040 — Treatment of materials: custom manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Custom manufacturing of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Manufacturing services for others in the field of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload antibody drug conjugates and intermediates thereof; Custom manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical preparations, biomedical preparations, drug conjugates, anti-body drug conjugates, chemical reagents; Biomanufacturing for others of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals using biological organisms in the manufacturing process
• Class 042 — Scientific and technological services: Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Research and development services of new pharmaceutical products; Research and development of antibody-drug conjugates; Research and development of conjugated antibodies; Product development consulting in the field of pharmaceuticals, anti-bodies, conjugated antibodies, chemical reagents; Product development for others; Biomedical research services; Scientific research in the nature of conducting clinical trials for others in the field of new pharmaceutical development

Owner

• WuXi XDC Cayman Inc., Grand Cayman, KY

Prosecution history

• 29 Oct 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 30 Sept 2026 — ASSIGNED TO EXAMINER
• 21 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 21 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 21 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 13 Aug 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 13 Aug 2026 — NON-FINAL ACTION E-MAILED
• 13 Aug 2026 — NON-FINAL ACTION WRITTEN
• 06 Aug 2026 — ASSIGNED TO EXAMINER
• 04 Aug 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 26 Mar 2026 — APPLICATION FILING RECEIPT MAILED
• 26 Mar 2026 — NEW APPLICATION ENTERED